Alector, Inc. Profile Avatar - Palmy Investing

Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment…

Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of ALEC's Analysis
CIK: 1653087 CUSIP: 014442107 ISIN: US0144421072 LEI: - UEI: -
Secondary Listings
ALEC has no secondary listings inside our databases.